menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

PsA + COVID-19: Conference Highlights From ACR Convergence 2020

What’s the latest data on managing psoriatic arthritis during the COVID-19 pandemic?

Live Broadcast
0.50 available credits
Information
November 17, 2020
09:00 PM - 09:30 PM EST
Online
PsA + COVID-19: Conference Highlights From ACR Convergence 2020
Choose a format
Details
Presenters
Related
Comments
  • Overview

    This 30-minute live broadcast focuses on highlights from the ACR Convergence 2020 conference. You will learn about new evidence regarding psoriatic arthritis (PsA) in the context of COVID-19 presented in a clinical discussion with the prominent rheumatology expert in this clinical area. This broadcast features the latest data synthesized to provide information most relevant to clinical practice. Topics include efficacy and safety of existing and novel targeted therapies for PsA and strategies for minimizing the risk of infections and adverse events for patients with PsA at the time of the COVID-19 pandemic.

    APPROVED ACR EDUCATION PARTNER: This activity is included in the ACR’s Education Partner program. Independent reporting and the viewpoints expressed are those of Forefront Collaborative and its affiliates and do not represent the ACR.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

    • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD; Christine Tebben

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    • Faculty Presenter: Philip J. Mease, MD, MACR
      • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
      • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
      • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
  • Target Audience

    The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

  • Learning Objectives

    As a result of participation in this educational activity, learners should be able to

    • Summarize findings from recent clinical trials on biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA
    • Discuss latest evidence about targeted synthetic DMARDs for treatment of PsA
    • Consider the impact of the COVID-19 pandemic on PsA care

  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Credit Designation Statement
    Forefront Collaborative designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative. 

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Details
Presenters
Related
Comments
Recommended
  • Overview

    This 30-minute live broadcast focuses on highlights from the ACR Convergence 2020 conference. You will learn about new evidence regarding psoriatic arthritis (PsA) in the context of COVID-19 presented in a clinical discussion with the prominent rheumatology expert in this clinical area. This broadcast features the latest data synthesized to provide information most relevant to clinical practice. Topics include efficacy and safety of existing and novel targeted therapies for PsA and strategies for minimizing the risk of infections and adverse events for patients with PsA at the time of the COVID-19 pandemic.

    APPROVED ACR EDUCATION PARTNER: This activity is included in the ACR’s Education Partner program. Independent reporting and the viewpoints expressed are those of Forefront Collaborative and its affiliates and do not represent the ACR.

  • Disclosure of Conflicts of Interest

    Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

    *The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

    The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

    • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD; Christine Tebben

    The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

    • Faculty Presenter: Philip J. Mease, MD, MACR
      • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
      • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
      • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
  • Target Audience

    The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

  • Learning Objectives

    As a result of participation in this educational activity, learners should be able to

    • Summarize findings from recent clinical trials on biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA
    • Discuss latest evidence about targeted synthetic DMARDs for treatment of PsA
    • Consider the impact of the COVID-19 pandemic on PsA care

  • Accreditation and Credit Designation Statements

    Accreditation Statement
    Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

    Credit Designation Statement
    Forefront Collaborative designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This activity is provided by Forefront Collaborative. 

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Programs 6/23/21